June 2013 Volume 9, Issue 6
Volume 9, Issue 6 | June 2013
June 2013
In this Issue
Diagnostics
The blind men and the elephant
Progress in developing diagnostic tests hampered by differing perspectives of stakeholders involvedGo-with-the-flow cytometry
CytoVas allies with BD Biosciences to develop Vascular Health ProfileNew hope for earlier autism diagnosis
Largest prospective multisite autism clinical study offers promise of ASD diagnosis at 18 monthsIntegrating the clinical lab workflow
CollabRx and GeneInsight collaborate on interpretation and reporting service for clinical genetic sequencingGlobal News
OPKO opts for PROLOR
Acquisition values PROLOR at $480 millionA partnership of VAST consequence
Proprietary chemistry platform will aid development of novel small molecules against multiple targetsTakeda acquires Inviragen for up to $250 million
Company gains promising vaccine candidates against dengue and hand, foot and mouth diseaseGoing small for broad potential
Nimbus Discovery teams with Shire to co-develop therapies for rare diseasesA novel Conceptus
Bayer HealthCare signs $1.1-billion merger agreement with Conceptus Inc.Omics & Systems Biology
Belfer Institute, Evotec forge oncology collaboration
The two parties aim to discover new oncology therapies targeting epigenetic mechanismGiant leap into genomic medicine
Jackson Laboratory, Connecticut hospitals explore new cancer therapies for children, adultsLaying a foundation for hematologic diagnostics
Foundation Medicine, MSKCC to co-develop product that will match patients with targeted therapies or clinical trials for hematologic malignanciesMaking sense of mutations
Collaboration seeks to understand genetic changes iPSCs acquire during differentiationResearch & Development
Signing a sweet deal
Pharma giants Merck and Pfizer enter worldwide collaboration agreement to develop and commercialize investigational medicine for type 2 diabetesWorking in Concert
Concert, Celgene to develop compounds for cancer, inflammationNew partner, new patent
Soligenix to expand biodefense and infectious disease product pipeline through collaboration with IntrexonFast-fail for success
UCLA gets $9 million in NIMH funding to conduct fast-fail trials in autism spectrum disordersStrength in numbers
According to analysts, pharmas and biotechs are turning to M&As and collaboration deals to fix ‘bloated, untenable’ R&D paradigmCommentary
Hire education: Which came first, the university or the economy?
A knowledge-based economy cannot thrive with frictions imposed by millennium-old constraints. At the limits where no one has a degree or everyone has a degree, the consequences are clearly dire. Too much of a good thing is a bad thing, and perhaps that’s where we are today in the United States.Your personal genome sequenced: Where do you go from here?
Rapid, informative and inexpensive DNA variation annotation represents the future for much of medical research, and will continue to serve as the basis for significant technology development in academic and industry settings.Publishers announce changes, broader focus for DDNEWS
There is something new about ddn...Our front cover this month shows a change, but it is more about ddn continuing to evolve with the news of the changing technology in pharma, biotech and life-science researchClinical Trials
The new math in clinical studies
Mathematical modeling of time-to-tumor growth helps predict survival benefit of bevacizumab for patients with metastatic colorectal cancerVetting the best candidates
Cancer Research UK and Clovis Oncology begin trial for breast and ovarian cancer drugTake it from the PROs
Study determines degree of patient involvement in implementing clinical trials for diabetesA heart-felt boost
Trevena and Forest Labs announce development collaboration for TRV027Stemming the pain of osteoarthritis
RNL BIO’s stem cell product holds promise of a single-injection treatment for osteoarthritisSpecial Reports
DNA: A winding string of achievements
Examining 60 years of scientific progress since the discovery of DNADNA: A winding string of achievements (continued)
Additional stories examining 60 years of scientific progress since the discovery of DNA...and looking forwardTools & Technology
Quicker than an NGS minute
QIAGEN acquires Ingenuity Systems, adding time-saving solution for analysis and interpretation of complex biological dataIn it to win it
Research indicates that open competition can be used to drive innovationSanofi sets sights on translational medicine
Partnership with NextBio will incorporate patient ‘omics and clinical data into pharma’s Translational Medicine for Patients programQuidel acquires BioHelix Corp.
Completion of the acquisition gains Quidel isothermal amplification platformsFeature
PEOPLE & PROMOTIONS: Pharma employment news
Find out who’s on the move in pharma and biotech
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
